AstraZeneca Reports Results of Roxadustat in P-III OLYMPUS and ROCKIES Studies for Chronic Kidney Disease Patients with Anaemia

 AstraZeneca Reports Results of Roxadustat in P-III OLYMPUS and ROCKIES Studies for Chronic Kidney Disease Patients with Anaemia

AstraZeneca Reports Results of Roxadustat in P-III OLYMPUS and ROCKIES Studies for Chronic Kidney Disease Patients with Anaemia

Shots:

  • The P-III OLYMPUS study involve assessing of Roxadustat vs PBO in 2,781 patients with anaemia (Hb<10.0g/dL) in a ratio (1:1) in non-dialysis-dependent -CKD stages, resulted in improvement in Hb levels (1.75g/dL vs 0.40g/dL) and improvement in Hb levels in patients with elevated hsCRP levels > 5mg/L (1.73 g/dL vs 0.62g/dL)
  • The P-III ROCKIES study involve assessing of Roxadustat vs epoetin alfa in 2,133 dialysis-dependent -CKD patients in a ratio (1:1) with anaemia either currently treated with an erythropoietin analogue (Hb<12g/dL) or not treated with an erythropoietin analogue (Hb<10g/dL), resulted in improvement in Hb level (0.77g/dL vs 0.68g/dL) and improvement in Hb level in patients with elevated hsCRP levels > 5mg/L (0.80g/dL vs  0.59g/dL)
  • Roxadustat is first-in-class, oral medicine and hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) being evaluated for the treatment of anaemia in chronic kidney disease with its anticipated regulatory submission in the US in Q4’19

Click here to­ read full press release/ article | Ref: AstraZeneca | Image: Bloomberg quint

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post